Eli Lilly Eyes India as Global Export Hub Amid Mounjaro's Soaring Sales

• Eli Lilly plans to make India a global supply chain hub, leveraging its $1 billion investment in contract manufacturing.
• Mounjaro, Lilly's weight-loss drug, doubled sales in India and became its top-selling medicine by value.
• The company intends to export locally produced drugs from India to markets worldwide, utilizing the country's contract manufacturing capabilities.
• Lilly also plans to introduce new products to India, including Alzheimer's drug donanemab and future obesity treatments.
• Despite competition and upcoming generic versions of rival drugs, Lilly remains confident in Mounjaro's efficacy and pricing strategy.